Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism

Breast Cancer Research and Treatment

Volumn 139, Issue 3, 2013, Pages 731-740

  Hanamura, Toru ^a,b   Niwa, Toshifumi ^a   Nishikawa, Sayo ^a   Konno, Hiromi ^a   Gohno, Tatsuyuki ^a   Tazawa, Chika ^a   Kobayashi, Yasuhito ^c   Kurosumi, Masafumi ^c   Takei, Hiroyuki ^c   Yamaguchi, Yuri ^c   Ito, Ken Ichi ^b   Hayashi, Shin Ichi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

Author keywords

Androgen metabolism; Androgen receptor; Aromatase inhibitor resistance; Breast cancer; MCF 7 cell

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 3BETA ANDROSTANEDIOL; 3BETA HYDROXYSTEROID DEHYDROGENASE 1; ANASTROZOLE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; LETROZOLE; TOREMIFENE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; COCULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; TESTOSTERONE METABOLISM;

ANDROGENS; ANDROSTANE-3,17-DIOL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DIHYDROTESTOSTERONE; DRUG RESISTANCE, NEOPLASM; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; MCF-7 CELLS; MULTIENZYME COMPLEXES; NITRILES; PROGESTERONE REDUCTASE; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; STEROID ISOMERASES; TESTOSTERONE; TRIAZOLES;

EID: 84879800727     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2595-x     Document Type: Article

References (36)

1. Andò S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M (2002) Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 193:121-128
2. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664-1670
3. Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S et al (2000) Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. The Breast 18(Suppl 2):S1-S11
4. Fang H, Tong W, Branham WS, Moland CL, Dial SL, Hong H, Xie Q, Perkins R, Owens W, Sheehan DM (2003) Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol 16:1338-1358
5. Hayashi S, Niwa T, Yamaguchi Y (2009) Estrogen signaling pathway and its imaging in human breast cancer. Cancer Sci 100:1773-1778
6. Heneweer M, Muusse M, Dingemans M, de Jong PC, van den Berg M, Sanderson JT (2005) Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicol Sci 83:257-263
7. Inoue A, Omoto Y, Yamaguchi Y, Kiyama R, Hayashi S (2004) Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cell. J Mol Endocrinol 32:649-661
8. Jin Y, Duan L, Lee SH, Kloosterboer HJ, Blair IA, Penning TM (2009) Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids. J Biol Chem 284:10013-10022
9. Koyama H, Iesato A, Fukushima Y, Okada T, Watanabe T, Harada M, Ito T, Maeno K, Mochizuki Y, Ito K et al (2011) A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer. Gan To Kagaku Ryoho 38:1123-1126
10. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863-870
11. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX, Pelletier G (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24:152-182
12. Lawrence MG, Lai J, Clements JA (2010) Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 31:407-446
13. Lorence MC, Murry BA, Trant JM, Mason JI (1990) Human 3 beta-hydroxysteroid dehydrogenase/delta 5 → 4 isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. Endocrinology 126:2493-2498
14. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A (2006) Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 66:7775-7782
15. Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M (2005) Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer 12(Suppl 1):S75-S84
16. Matsumoto M, Yamaguchi Y, Seino Y, Hatakeyama A, Takei H, Niikura H, Ito K, Suzuki T, Sasano H, Yaegashi N et al (2008) Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr Relat Cancer 15:451-463
17. Miller WR, Anderson TJ, Jack WJ (1990) Relationship between tumour aromatase activity, tumour characteristics and response to therapy. J Steroid Biochem Mol Biol 37:1055-1059
18. O'Neill JS, Miller WR (1987) Aromatase activity in breast adipose tissue from women with benign and malignant breast disease. Br J Cancer 56:601-604
19. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y et al (2001) Expression, function, and clinical implications of the estrogen receptor β in human lung cancers. Biochem Biophys Res Commun 285:340-347
20. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T (2002) Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 16:113-120
21. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA (2000) Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 167:139-150
22. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL et al (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69:6131-6140
23. Sabnis G, Brodie A (2010) Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Mol Cell Endocrinol 340(2):142-147
24. Santen RJ, Santner SJ, Pauley RJ, Tait L, Kaseta J, Demers LM, Hamilton C, Yue W, Wang JP (1997) Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol 61:267-271
25. Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H (2008) Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 630:19-34
26. Santner SJ, Chen S, Zhou D, Korsunsky Z, Martel J, Santen RJ (1993) Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture. J Steroid Biochem Mol Biol 44:611-616
27. Sasano H, Ozaki M (1997) Aromatase expression and its localization in human breast cancer. J Steroid Biochem Mol Biol 61:293-298
28. Sasano H, Miki Y, Nagasaki S, Suzuki T (2009) In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol Int 59:777-789
29. Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME, Rae JM (2009) The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat 115:289-296
30. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B, Penning TM (2004) Human cytosolic 3 alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3 beta-hydroxysteroid dehydrogenase activity. J Biol Chem 279:10784-10795
31. Takagi K, Miki Y, Nagasaki S, Hirakawa H, Onodera Y, Akahira J, Ishida T, Watanabe M, Kimijima I, Hayashi S et al (2010) Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocr Relat Cancer 17:415-430
32. Thürlimann B, Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J, Arimidex Study Group (2003) Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39:2310-2317
33. Wang P, Wen Y, Han G-Z, Sidhu PK, Zhu BT (2009) Characterization of the oestrogenic activity of non-aromatic steroids: are there male-specific endogenous oestrogen receptor modulators? Br J Pharmacol 158:1796-1807
34. Yamaguchi Y, Takei H, Suemasu K, Kobayashi Y, Kurosumi M, Harada N, Hayashi S (2005) Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res 65:4653-4662
35. Yamamoto Y, Masuda N, Ohtake T, Yamashita H, Saji S, Kimijima I, Kasahara Y, Ishikawa T, Sawaki M, Hozumi Y et al (2010) Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. Breast Cancer 17:254-260
36. Yue W, Fan P, Wang J, Li Y, Santen RJ (2007) Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 106:102-110